BiotechTube

Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXd

Phase 1/2Recruiting
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastroesophageal Junction

Conditions

Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer

Trial Timeline

Aug 7, 2024 → Aug 8, 2030

NCT ID
NCT06445972

About Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXd

Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXd is a phase 1/2 stage product being developed by Daiichi Sankyo for Gastroesophageal Junction. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06445972. Target conditions include Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms.

What happened to similar drugs?

3 of 20 similar drugs in Gastroesophageal Junction were approved

Approved (3) Terminated (1) Active (17)
🔄Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
🔄zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
🔄E3810 + E3810 + PlaceboEisaiPhase 3
🔄Rabeprazole ER + RanitidineEisaiPhase 3
✅rabeprazole and pantoprazoleEisaiApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06445972Phase 1/2Recruiting

Competing Products

20 competing products in Gastroesophageal Junction

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
35
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
FamotidineAstellas PharmaPhase 2/3
38
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
28
E3810 + E3810 + PlaceboEisaiPhase 3
40
Rabeprazole ER + RanitidineEisaiPhase 3
40
E3710 + E3710EisaiPhase 1
29
rabeprazole and pantoprazoleEisaiApproved
43
Rabeprazole 20 mgEisaiPhase 2
35
rabeprazole sodiumEisaiPhase 2
35
RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUMEisaiPhase 3
40
Rabeprazole sodium + EsomeprazoleEisaiPhase 3
40
rabeprazole sodium + PlaceboEisaiPhase 3
40
Rabeprazole + Rabeprazole + Rabeprazole + RabeprazoleEisaiPhase 3
40